- Termination of Registration of a Class of Security under Section 12(g) (15-12G)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number:  001-32581

LOTUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada		20-0507918
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

16 Cheng Zhuang Road, Feng Tai District, Beijing 100071

People’s Republic of China

86-10-63899868

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

	Rule 12g-4(a)(1)	x	Rule 15d-6	o
	Rule 12g-4(a)(2)	o
	Rule 12h-3(b)(1)(i)	o
	Rule 12h-3(b)(1)(i)(ii)	o
Approximate number of holders of record as of the certification or notice date:	77

---

Pursuant to the requirements of the Securities Exchange Act of 1934, Lotus Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

DATE:	May 11, 2012		By:	/s/ Liu Zhongyi
				Liu Zhongyi
				Chief Executive Officer

---